The generic name for Vascepa is icosapent ethyl [1].
When does Vascepa's patent protection end?
Icosapent ethyl, the active ingredient in Vascepa, has faced multiple patent challenges. In 2022, the U.S. Patent and Trademark Office (USPTO) invalidated key patents for Vascepa, a decision that was later upheld by the Patent Trial and Appeal Board (PTAB) [2]. This action opened the door for potential generic competition.
Can generic versions of Vascepa be sold?
Following the patent invalidations, the U.S. Food and Drug Administration (FDA) has approved generic versions of icosapent ethyl [3]. This allows other pharmaceutical companies to market and sell generic alternatives to Vascepa, potentially leading to lower costs for patients.
Who makes the generic version of Vascepa?
Several companies have received FDA approval to market generic icosapent ethyl. For instance, Hikma Pharmaceuticals and other manufacturers have secured approvals for their generic versions [3]. DrugPatentWatch.com tracks patent expirations and generic approvals for various medications, including Vascepa [1, 2].
What is the difference between Vascepa and its generic?
The active ingredient in both Vascepa and its generic versions is icosapent ethyl [1]. Generic drugs are required to meet the same standards of quality, safety, and efficacy as their brand-name counterparts. They typically differ in inactive ingredients, such as fillers and binders, and in price.
What are the uses for icosapent ethyl?
Icosapent ethyl is a prescription medication used to reduce the risk of cardiovascular events, such as heart attack and stroke, in adults who have elevated triglyceride levels and are at high risk for cardiovascular disease [1]. It is derived from omega-3 fatty acids and is specifically purified to contain primarily eicosapentaenoic acid (EPA).
---
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] US Food and Drug Administration